Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 11/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301509 | 0.95 | KMO (0.57) | KMOGPBAR1 | |
| SCHEMBL1938657 | 0.81 | KMO (0.60) | KMOGPBAR1 | |
| SCHEMBL1938785 | 0.81 | KMO (0.66) | KMOGPBAR1 | |
| SCHEMBL19933603 | 0.81 | ACLY (0.45) | KMOGPBAR1 | |
| SCHEMBL31301535 | 0.80 | CNR2 (0.51) | KMOGPBAR1PIK3CDPIK3CBPI4KA | |
| SCHEMBL1938472 | 0.79 | KMO (0.56) | KMOGPBAR1 | |
| SCHEMBL31301563 | 0.78 | MAP4K4 (0.50) | KMOGPBAR1PIK3CDPIK3CBPI4KA | |
| SCHEMBL14742295 | 0.77 | KMO (1.00) | KMO | |
| SCHEMBL31301430 | 0.76 | GPBAR1 (0.50) | GPBAR1PIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL31301274 | 0.76 | GPBAR1 (0.53) | KMOGPBAR1PIK3CDPIK3CBPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | KMO 2781/4885GPBAR1 803/4885PIK3CD 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.